Related Experiment Video
Updated: Jun 10, 2026
08:39
Magnetic and Thermal-sensitive Poly(N-isopropylacrylamide)-based Microgels for Magnetically Triggered Controlled Release
Published on: July 4, 2017
Mucoadhesive controlled release microcapsules of indomethacin: optimization and stability study
Hany M Ibrahim1, Tarek A Ahmed, Ahmed E A Lila
1Department of Pharmaceutics and Industrial Pharmacy, Al-Azhar University, Cairo, Egypt.
Journal of Microencapsulation
|August 10, 2010
Summary
Researchers developed optimized indomethacin microcapsules using mucoadhesive polymers. These microcapsules offer high drug entrapment and controlled release for effective, twice-daily oral administration.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
Background:
- Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) requiring controlled release for improved therapeutic efficacy and reduced side effects.
- Developing effective drug delivery systems is crucial for optimizing the pharmacokinetic profile of NSAIDs like indomethacin.
Purpose of the Study:
- To develop and optimize indomethacin microcapsules using a blend of mucoadhesive polymers.
- To achieve high drug entrapment, enhanced mucoadhesiveness, and sustained drug release over an extended period.
Main Methods:
- Microcapsules were prepared using the orifice-ionic gelation method with polymers including sodium alginate, sodium carboxymethylcellulose, methylcellulose, Carbopol 934, and hydroxypropyl methylcellulose.
- A mixture statistical design was employed to study the effects of polymer composition on microcapsule properties.
- Mucoadhesive properties were assessed using an everted intestinal sac test.
Main Results:
- Drug entrapment efficiency ranged from 68% to 94%, influenced by polymer type.
- Drug release extended over 12 hours, with 92-100% release observed.
- The optimized formulation demonstrated 89.3% drug entrapment, 94.8% drug release, and 30.4% mucoadhesiveness.
- All formulations exhibited stability for over 1.5 years.
Conclusions:
- Optimized mucoadhesive microcapsules show significant potential for the controlled oral delivery of indomethacin.
- The developed system allows for a convenient twice-daily dosing regimen, improving patient compliance.
- The combination of mucoadhesive polymers effectively enhances drug delivery characteristics for indomethacin.
More Related Videos
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...